CHANGCHUN BCHT BIOTECHNOLOGY CO. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.54 CNY | -1.49% |
|
-2.55% | -10.23% |
| 10-25 | Changchun BCHT Biotechnology Co. Reports Earnings Results for the Nine Months Ended September 30, 2024 | CI |
| 08-16 | Changchun BCHT Biotechnology H1 Profit Up 24%, Operating Income Rises 11% | MT |
Sales 2023 by Business Segment
Sales 2023 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
Biotechnology | 976M | 1.44B | 1.2B | 1.07B | 1.82B | |
Total Assets | 1.58B | 2.47B | 4.17B | 4.28B | 5.05B | |
Interest Expense | -8.3M | -4.05M | -329K | - | -705K | |
Income Tax Expense | 42.81M | 68.42M | 18.01M | 16.16M | 62.75M | |
CAPEX | -128M | -336M | -633M | -291M | -471M | |
EBT | 264M | 487M | 262M | 198M | 564M | |
D&A | 42.76M | 58.86M | 68.34M | 70.94M | 91.99M | |
Operating Income | 268M | 482M | 262M | 187M | 559M | |
Net Income | 221M | 418M | 244M | 182M | 501M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
Eastern Region | 333M | 515M | 385M | 340M | 502M | |
Central China | 164M | 259M | 152M | 134M | 290M | |
Southern Region | 190M | 212M | 208M | 217M | 282M | |
Southwest | 105M | 183M | 144M | 139M | 281M | |
Northern Region | 89.02M | 103M | 118M | 95.58M | 195M | |
North-West Area | 51.18M | 89.81M | 121M | 86.52M | 142M | |
Northeast District | 36.17M | 69.7M | 50.86M | 39.25M | 96.42M | |
Foreign | 6.07M | 8.44M | 18.21M | 20.16M | 35.16M | |
Hong Kong, Macao and Taiwan | - | - | 5M | - | - |
- Stock Market
- Equities
- 688276 Stock
- Financials Changchun BCHT Biotechnology Co.
- Business Segments
MarketScreener is also available in this country: United States.
Switch edition